Patents by Inventor Charles Antzelevitch
Charles Antzelevitch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9056108Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: GrantFiled: March 20, 2014Date of Patent: June 16, 2015Assignee: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Publication number: 20140323493Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: ApplicationFiled: March 20, 2014Publication date: October 30, 2014Applicant: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Patent number: 8754087Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: GrantFiled: May 31, 2013Date of Patent: June 17, 2014Assignee: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Publication number: 20130317038Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: ApplicationFiled: May 31, 2013Publication date: November 28, 2013Applicant: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Patent number: 8513254Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: GrantFiled: December 20, 2010Date of Patent: August 20, 2013Assignee: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Publication number: 20120046299Abstract: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.Type: ApplicationFiled: July 25, 2011Publication date: February 23, 2012Inventors: Luiz Belardinelli, Charles Antzelevitch, Brent Blackburn
-
Publication number: 20110183990Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: ApplicationFiled: December 20, 2010Publication date: July 28, 2011Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Patent number: 7968296Abstract: Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: GrantFiled: October 8, 2010Date of Patent: June 28, 2011Inventors: Charles Antzelevitch, Guido Pollevick
-
Publication number: 20110053165Abstract: Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: ApplicationFiled: October 8, 2010Publication date: March 3, 2011Applicant: MASONIC MEDICAL RESEARCH LABORATORYInventors: Charles Antzelevitch, Guido Pollevick
-
Patent number: 7833718Abstract: Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: GrantFiled: November 6, 2007Date of Patent: November 16, 2010Assignee: Masonic Medical Research LaboratoryInventors: Charles Antzelevitch, Guido Pollevick
-
Patent number: 7745213Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: GrantFiled: March 30, 2009Date of Patent: June 29, 2010Assignee: Masonic Medical Research LaboratoryInventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
-
Publication number: 20100056536Abstract: The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: ApplicationFiled: September 3, 2009Publication date: March 4, 2010Inventors: Charles Antzelevitch, Alexander Burashnikov, John Shryock, Sridharan Rajamani, Luiz Belardinelli
-
Publication number: 20100004255Abstract: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.Type: ApplicationFiled: September 9, 2009Publication date: January 7, 2010Inventors: Luiz Belardinelli, Charles Antzelevitch, Brent Blackburn
-
Publication number: 20090317905Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: ApplicationFiled: March 30, 2009Publication date: December 24, 2009Applicant: MASONIC MEDICAL RESEARCH LABORATORYInventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
-
Patent number: 7537928Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: GrantFiled: August 23, 2004Date of Patent: May 26, 2009Assignee: Masonic Medical Research LaboratoryInventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
-
Publication number: 20080118438Abstract: Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: ApplicationFiled: November 6, 2007Publication date: May 22, 2008Inventors: Charles Antzelevitch, Guido Pollevick
-
Publication number: 20080109040Abstract: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.Type: ApplicationFiled: October 31, 2007Publication date: May 8, 2008Inventors: Luiz Belardinelli, Charles Antzelevitch, Brent Blackburn
-
Publication number: 20050130190Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.Type: ApplicationFiled: August 23, 2004Publication date: June 16, 2005Inventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
-
Publication number: 20030220344Abstract: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.Type: ApplicationFiled: April 3, 2003Publication date: November 27, 2003Inventors: Luiz Belardinelli, Charles Antzelevitch, Brent Blackburn